The Manufacturers Life Insurance Company Acquires 20,413 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

The Manufacturers Life Insurance Company increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 23.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 107,195 shares of the medical research company's stock after buying an additional 20,413 shares during the period. The Manufacturers Life Insurance Company owned 0.38% of Bio-Rad Laboratories worth $35,215,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BIO. Venturi Wealth Management LLC boosted its position in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after acquiring an additional 87 shares during the period. GeoWealth Management LLC grew its position in shares of Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Picton Mahoney Asset Management increased its holdings in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the period. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. Finally, UMB Bank n.a. boosted its stake in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 65.24% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on BIO. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Citigroup cut their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research report on Friday. UBS Group decreased their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday. Royal Bank of Canada cut their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $327.40.

Bio-Rad Laboratories Price Performance

NYSE BIO traded up $3.97 during trading on Monday, hitting $240.31. 286,792 shares of the company's stock were exchanged, compared to its average volume of 320,278. The stock's 50 day moving average price is $246.93 and its two-hundred day moving average price is $304.68. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company has a market cap of $6.73 billion, a PE ratio of -3.69 and a beta of 1.12.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm's quarterly revenue was down 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.30 EPS. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.